Key facts
- BrightHeart’s last known valuation is $234.8M (Jan 2026).
- It has raised $15.1M; the latest was Later Stage VC ($12.9M) in Jan 2026.
- Notable investors include Sofinnova Partners, GO Capital, Odyssee Venture, Lift Value, John Gridley — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for BrightHeart
- ·The full record, as it builds
Funding rounds
No funding rounds for BrightHeart are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BrightHeart
Developer of an artificial intelligence-driven ultrasound screening software designed to detect congenital heart defects in fetuses. The company's software provides real-time guidance by consistently performing prenatal ultrasounds and informing decisions to optimize pregnancy and delivery management, enabling clinicians to access support for prenatal identification of congenital heart defects.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2020
- Employees
- 10
- Website
- brightheart.ai/
- Ownership
- Privately Held (backing)
BrightHeart doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BrightHeart shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BrightHeart in its N-PORT filings yet. We sweep new filings monthly.